223Ra Induces Transient Functional Bone Marrow Toxicity

Authors

Maria Parlani
Francesco Boccalatte
Anna Yeaton
Feng Wang
Jianhua Zhang
Iannis Aifantis
Eleonora Dondossola

Publication Date

10-1-2022

Journal

Journal of Nuclear Medicine

Abstract

223Ra is a bone-seeking, α-particle-emitting radionuclide approved for the treatment of patients with metastatic prostate cancer and is currently being tested in a variety of clinical trials for primary and metastatic cancers to bone. Clinical evaluation of 223Ra hematologic safety showed a significantly increased rate of neutropenia and thrombocytopenia in patients, hinting at myelosuppression as a side effect. Methods: In this study, we investigated the consequences of 223Ra treatment on bone marrow biology by combining flow cytometry, single-cell RNA sequencing, three-dimensional multiphoton microscopy and bone marrow transplantation analyses. Results: 223Ra accumulated in bones and induced zonal radiation damage confined to the bone interface, followed by replacement of the impaired areas with adipocyte infiltration, as monitored by 3-dimensional multiphoton microscopy ex vivo. Flow cytometry and single-cell transcriptomic analyses on bone marrow hematopoietic populations revealed transient, nonspecific 223Ra-mediated cytotoxicity on resident populations, including stem, progenitor, and mature leukocytes. This toxicity was paralleled by a significant decrease in white blood cells and platelets in peripheral blood-an effect that was overcome within 40 d after treatment. 223Ra exposure did not impair full hematopoietic reconstitution, suggesting that bone marrow function is not permanently hampered. Conclusion: Our results provide a comprehensive explanation of 223Ra reversible effects on bone marrow cells and exclude long-term myelotoxicity, supporting safety for patients.

Keywords

Alpha Particles, Bone Marrow, Bone and Bones, Flow Cytometry, Humans, Male, Radioisotopes, 223Ra, myelotoxicity, bone marrow

Comments

PMID: 35177425

DOI

10.2967/jnumed.121.263310

PMID

35177425

PMCID

PMC9536707

PubMedCentral® Posted Date

October 2022

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes